Clinical Trials Logo

Clinical Trial Summary

In the first phase, it mainly explores the safety, tolerability and preliminary effectiveness of two doses of OH2 injection in the treatment of patients with recurrent central nervous system tumors; to evaluate the biodistribution and virus shedding of OH2 injection administered in the tumor cavity; to evaluate the level of anti-HSV2 antibody in patients when OH2 injection is administered intracavitary to tumor; to determine the phase II recommended dose (RP2D) of OH2 injection in the treatment of recurrent glioblastoma. Phase IIa, to evaluate the preliminary efficacy of OH2 injection in the treatment of patients with recurrent glioblastoma after surgery, and to further evaluate the safety of OH2 in the treatment of relapsed glioblastoma.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05235074
Study type Interventional
Source Binhui Biopharmaceutical Co., Ltd.
Contact Wenbin Li
Phone 15301377998
Email neure55@126.com
Status Recruiting
Phase Phase 1/Phase 2
Start date November 16, 2021
Completion date June 15, 2025

See also
  Status Clinical Trial Phase
Completed NCT00876993 - Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors Phase 1
Completed NCT00003935 - Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma Phase 1
Terminated NCT00107471 - Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma Phase 1/Phase 2
Completed NCT00003573 - Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma Phase 2
Suspended NCT05308407 - POWER UP: Participating Online While Exercising to Recover Using Play N/A
Terminated NCT00477503 - Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA Phase 1
Active, not recruiting NCT01985451 - Pemetrexed and Temozolomide in Treating Patients With Relapsed Primary Central Nervous System Lymphoma (PCNSL) Phase 2
Withdrawn NCT00109798 - Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma N/A
Completed NCT00003141 - Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Infants With Malignant Brain or Spinal Cord Tumors Phase 1
Completed NCT00003203 - Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors Phase 2
Completed NCT02462629 - Study of BLZ-100 in Pediatric Subjects With CNS Tumors Phase 1
Active, not recruiting NCT01735747 - Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS Lymphoma Phase 2
Recruiting NCT00607984 - Administration of High Dose Thiotepa and Melphalan With Autologous Hematopoietic Stem Cell Transplant in Children and Adolescents With Solid Tumors N/A
Completed NCT00899834 - DNA Analysis of Tumor Tissue Samples From Patients With Diffuse Brain Stem Glioma N/A
Completed NCT00066248 - Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Phase 2
Completed NCT00187226 - A Study for Image-Guided Radiation Therapy in Pediatric Brain Tumors and Side Effects Phase 2
Completed NCT02793466 - Durvalumab in Pediatric and Adolescent Patients Phase 1
Withdrawn NCT01052363 - OXC401-PO1s/WVU 1309 - A Pilot Study of Fosbretabulin With Bevacizumab in Recurrent High-Grade Gliomas Phase 1
Completed NCT00047320 - Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors Phase 2
Completed NCT00945828 - Assessing the Effectiveness of Individual Education Plans for Childhood Cancer Survivors N/A